How large is the cancer anorexia-cachexia syndrome (cacs) market, and what is its growth trajectory?
The cancer anorexia-cachexia (CACS) syndrome market size has grown rapidly in recent years. It will grow from $3.51 billion in 2024 to $3.89 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to rising incidence of cancer, growing awareness among healthcare professionals, increased focus on quality of life for cancer patients, expansion of clinical trials, pharmaceutical collaborations, and partnerships.
The cancer anorexia-cachexia (CACS) market size is expected to see rapid growth in the next few years. It will grow to $5.84 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increased cancer survival rates, rising investments in oncology supportive care, growth in personalized medicine, increasing focus on multimodal therapies, and growing healthcare infrastructure. Major trends in the forecast period include advancements in palliative care, development of targeted therapies, technological advancements in drug delivery systems, integration of AI in drug development, and personalized medicine.
Get Your Free Sample of The Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp
What are the key forces behind the cancer anorexia-cachexia syndrome (cacs) market’s growth in recent years?
Growing prevalence of cancer expected to propel the growth of the cancer anorexia-cachexia syndrome market going forward. Cancer is a broad term for a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Cancer rates are rising globally due to factors such as an aging population, lifestyle changes, environmental exposures, improved detection methods, and increased awareness, along with genetic predispositions and infections linked to certain cancers. Cancer anorexia-cachexia syndrome (CACS) helps address the growing prevalence of cancer by focusing on managing the severe weight loss and malnutrition often seen in cancer patients, improving their overall quality of life and treatment outcomes. For instance, in August 2024, according to a report published by the Macmillan Cancer Support, a UK-based charitable organization, over 3 million people in the UK are living with cancer, and this number is expected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the growing prevalence of cancer is driving the growth of the cancer anorexia-cachexia syndrome market.
Impact Of Increasing Healthcare Expenditure On The Market
Increasing healthcare expenditure is expected to propel the growth of the cancer anorexia-cachexia syndrome market going forward. Healthcare expenditure refers to the total amount of financial resources spent on Healthcare, including public and private sector spending. Increasing healthcare expenditure is driven by factors such as the aging population, rising prevalence of chronic diseases, advancements in medical technology, and higher demand for quality Healthcare. Cancer Anorexia-Cachexia Syndrome (CACS) drives increasing healthcare expenditure by necessitating specialized treatments, nutritional support, and palliative care for patients, contributing to higher costs for managing cancer-related complications. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the cancer anorexia-cachexia syndrome market.
What are the major segments of the cancer anorexia-cachexia syndrome (cacs) market?
The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented –
1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration
5) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions
Order your report now for swift delivery
Which companies dominate the cancer anorexia-cachexia syndrome (cacs) market?
Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.
What major trends will shape the cancer anorexia-cachexia syndrome (cacs) market during the forecast period?
Major companies operating in the cancer anorexia-cachexia syndrome market are focusing on developing innovative solutions, such as monoclonal antibody therapies, to enhance treatment efficacy, improve patient outcomes, and address unmet clinical needs. Monoclonal antibody therapies are treatments that use laboratory-produced antibodies designed to target specific antigens on cancer cells, helping the immune system recognize and attack them more effectively. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, announced positive results from a Phase II clinical trial of ponsegromab, a monoclonal antibody targeting Growth/Differentiation Factor 15 (GDF-15). The positive data from the study offers hope for a new treatment avenue for patients who suffer from this debilitating condition, for which few effective therapies currently exist. The Phase 2 trial results suggest significant progress in addressing the underlying inflammatory processes contributing to muscle loss and weight decline in cancer patients. This treatment approach aims not only to improve physical function but also to enhance the overall quality of life for cancer patients, marking a pivotal step in oncology care.
What are the key regional dynamics of the cancer anorexia-cachexia syndrome (cacs) market, and which region leads in market share?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cancer Anorexia-Cachexia Syndrome (CACS) Market Report 2025 Offer?
The cancer anorexia-cachexia syndrome (cacs) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition commonly seen in cancer patients, marked by severe metabolic disturbances. It involves a combination of inflammatory responses, hormonal changes, and altered nutrient utilization, often leading to poor prognosis and treatment resistance.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
